Jemperli (dostarlimab-gxly) / AnaptysBio, GSK  >>  Phase 1
Welcome,         Profile    Billing    Logout  

14 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jemperli (dostarlimab-gxly) / GSK
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT03307785: Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Active, not recruiting
1
58
US
Niraparib, Zejula, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, Avastin, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Tesaro, Inc.
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
02/20
08/24
CITRINO, NCT03250832: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Checkmark Data from CITRINO trial in combination with TSR-033 in advanced solid tumors
Nov 2018 - Nov 2018: Data from CITRINO trial in combination with TSR-033 in advanced solid tumors
Completed
1
111
Europe, US
TSR-033, LAG-3, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Tesaro, Inc., GlaxoSmithKline
Neoplasms
06/22
02/23
INDUCE-1, NCT02723955: Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors

Completed
1
829
Europe, Canada, Japan, US, RoW
feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa
GlaxoSmithKline, Merck Sharp & Dohme LLC
Neoplasms
07/23
07/23
NCT03843359: A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Active, not recruiting
1
98
Europe, Canada, Japan, US, RoW
GSK3745417, Dostarlimab
GlaxoSmithKline
Neoplasms
03/25
03/25
STARKAP, NCT05646082: Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

Recruiting
1
20
Europe
Dostarlimab in Combination Antiretroviral Therapy
Imperial College London
Refractory HIV Associated Kaposi Sarcoma
05/24
09/25
NCT04673448: Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
1
18
US
Dostarlimab, ANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042, Dostarlimab-gxly, Jemperli, Niraparib, MK-4827, MK4827
University of Washington, GlaxoSmithKline
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA-Associated Ovarian Carcinoma, Metastatic BRCA-Associated Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
09/24
03/26
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Recruiting
1
244
Canada, Japan, US, RoW
GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448
GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics
Neoplasms
09/25
09/25
NCT03955978: TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Recruiting
1
18
US
TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response
Washington University School of Medicine, Tesaro, Inc.
Endometrial Cancer, Cancer of the Endometrium
09/25
07/26
NCT05819892: Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Recruiting
1
21
US
Paclitaxel, Taxol, Carboplatin, Paraplatin®, Dostarlimab, Cisplatin, Platinol®-AQ, Platinol®, CDDP
M.D. Anderson Cancer Center, GlaxoSmithKline
Endometrial Cancer
03/26
03/28
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Data from the GARNET study in solid tumor at ASCO GI 2020
Jan 2021 - Jan 2021: Data from the GARNET study in solid tumor at ASCO GI 2020
Checkmark Data from the GARNET study in recurrent or advanced endometrial cancer at ESMO 2020
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
162
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, GSK4428859A
GlaxoSmithKline
Neoplasms
10/26
10/26
SCOOP, NCT04544995 / 2020-002359-39: Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors

Suspended
1
116
Europe, RoW
Niraparib, Dostarlimab
GlaxoSmithKline
Neoplasms
09/28
04/29

Download Options